Juno Therapeutics (JUNO) Misses Q2 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Juno Therapeutics Reports Second Quarter 2016 Financial Results
August 4, 2016 4:09 PM EDT- Strong cash position of $1.11 billion -
- JCAR015 Phase II ROCKET trial resumes enrollment -
- JCAR015 U.S. approval projected as early as the first half of 2018 -
- Preliminary JCAR017 Phase I NHL data show encouraging efficacy and toxicity profile -
- Eight product candidates in clinical trials against six different targets -
- Juno reaffirms cash burn guidance -
- Conference call today at 5:00 p.m. Eastern Time -
... More